Free tool
FAERS Monitor: Emrelis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761384 or its brand name (Emrelis, Telisotuzumab Vedotin-Tllv). Reports on generic versions are filed under their own applications.
Reports
78
Serious
34
44% of reports
Hospitalization
18
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use8
- neuropathy peripheral7
- keratitis6
- disease progression5
- interstitial lung disease4
- pneumonia4
- vision blurred4
- death3
- pneumonitis3
- agranulocytosis2
- fatigue2
- ocular toxicity2
- product storage error2
- product temperature excursion issue2
- pulmonary embolism2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 23 |
| 2026 | 50 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,081 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| keratitisSignal | 6 | 533.3 | 247.0 | 2,673 |
| ocular toxicity | 2 | 489.9 | 124.6 | 547 |
| product temperature excursion issue | 2 | 105.0 | 26.7 | 115 |
| pneumonitisSignal | 3 | 29.7 | 9.8 | 57 |
| agranulocytosis | 2 | 29.0 | 7.4 | 30 |
| interstitial lung diseaseSignal | 4 | 22.3 | 8.6 | 62 |
| neuropathy peripheralSignal | 7 | 19.8 | 9.8 | 108 |
| disease progressionSignal | 5 | 11.4 | 4.9 | 38 |
| vision blurredSignal | 4 | 7.9 | 3.0 | 18 |
| product storage error | 2 | 6.2 | 1.6 | 4 |
| pulmonary embolism | 2 | 5.7 | 1.4 | 4 |
| pneumoniaSignal | 4 | 3.3 | 1.3 | 4 |
| off label useSignal | 8 | 2.5 | 1.3 | 6 |
| death | 3 | 0.9 | 0.3 | 0 |
| fatigue | 2 | 0.7 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.